Enveda Raises $55M to Boost AI-Driven Drug Discovery

Funding and Support: Enveda Biosciences secured $55 million in funding with contributions from Microsoft and other investors.
AI-Powered Platform: The company’s AI platform accelerates drug discovery by analyzing chemical compounds, especially those from plants.
Data-Rich Database: Enveda has collected data on 38,000 medicinal plants related to 12,000 diseases and symptoms.

Enhanced Research: The funding will help Enveda advance its AI platform, improving drug discovery efficiency and accuracy.
Microsoft Partnership: In addition to capital, Microsoft provides cloud computing credits, boosting Enveda’s technological capabilities.
Targeted Drug Development: The investment supports Enveda’s programs focusing on skin conditions and bowel disease, moving towards clinical trials.
AI Integration: Enveda’s use of AI, based on Transformer architecture, automates complex chemical analysis, speeding up research.
Global Reach: The platform’s ability to probe “dark chemical space” promises to uncover new medicines from unexplored compounds.

Eksentricity